

Julie Chao

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1098000/julie-chao-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184
papers

7,804
citations

53
h-index

75
g-index

185
ext. papers

8,285
ext. citations

5.7
avg, IF

5.57
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 184 | Protective role of kallistatin in renal fibrosis via modulation of Wnt/ β -catenin signaling. <i>Clinical Science</i> , 2021 , 135, 429-446 | 6.5 | 6 |
| 183 | Human tissue kallikrein in the treatment of acute ischemic stroke. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286418821918 | 6.6 | 10 |
| 182 | Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 4387-4398 | 5.6 | 19 |
| 181 | Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation. <i>Oxidative Medicine and Cellular Longevity</i> , 2018 , 2018, 4138560 | 6.7 | 28 |
| 180 | Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. <i>Journal of the American Heart Association</i> , 2018 , 7, e009562 | 6 | 10 |
| 179 | Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. <i>Aging Cell</i> , 2017 , 16, 837-846 | 9.9 | 59 |
| 178 | Kallistatin suppresses cancer development by multi-factorial actions. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 71-78 | 7 | 10 |
| 177 | Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 5025610 | 6.7 | 14 |
| 176 | Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 5262958 | 6.7 | 11 |
| 175 | Plasma kallistatin in critically ill patients with severe sepsis and septic shock. <i>PLoS ONE</i> , 2017 , 12, e0178387 | 3.7 | 11 |
| 174 | Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. <i>Biological Chemistry</i> , 2017 , 398, 1309-1317 | 4.5 | 11 |
| 173 | Protective Role of Kallistatin in Vascular and Organ Injury. <i>Hypertension</i> , 2016 , 68, 533-41 | 8.5 | 36 |
| 172 | Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. <i>Experimental Cell Research</i> , 2016 , 340, 305-14 | 4.2 | 43 |
| 171 | Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5619-30 | 5.9 | 14 |
| 170 | Kallistatin inhibits TGF- β -induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. <i>Experimental Cell Research</i> , 2015 , 337, 103-10 | 4.2 | 62 |
| 169 | Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. <i>Scientific Reports</i> , 2015 , 5, 12463 | 4.9 | 53 |
| 168 | Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. <i>Critical Care</i> , 2015 , 19, 200 | 10.8 | 24 |

| | | | |
|-----|---|------|----|
| 167 | Adenovirus-mediated eNOS expression augments liver injury after ischemia/reperfusion in mice. <i>PLoS ONE</i> , 2014 , 9, e93304 | 3.7 | 11 |
| 166 | Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. <i>Immunology</i> , 2014 , 142, 216-26 | 7.8 | 37 |
| 165 | Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. <i>Journal of the American Heart Association</i> , 2014 , 3, e001194 | 6 | 23 |
| 164 | Kallikrein-kinin in stem cell therapy. <i>World Journal of Stem Cells</i> , 2014 , 6, 448-57 | 5.6 | 6 |
| 163 | Tissue kallikrein-kinin therapy in hypertension and organ damage. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 2014 , 69, 37-57 | | 4 |
| 162 | Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 642-6 | 12.7 | 18 |
| 161 | Tissue kallikrein is related to the severity of coronary artery disease. <i>Clinica Chimica Acta</i> , 2013 , 423, 90-8 | 6.2 | 6 |
| 160 | Kallistatin antagonizes Wnt/ β -catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. <i>Molecular and Cellular Biochemistry</i> , 2013 , 379, 295-301 | 4.2 | 33 |
| 159 | Plasma kallistatin levels in patients with severe community-acquired pneumonia. <i>Critical Care</i> , 2013 , 17, R27 | 10.8 | 27 |
| 158 | Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5366-72 | 5.9 | 32 |
| 157 | Human Kallikrein 1, Tissue Kallikrein 2013 , 2757-2761 | | |
| 156 | Mouse Kallikrein 9, Epidermal Growth Factor-binding Protein 2013 , 2830-2831 | | |
| 155 | Rat Tissue Kallikrein 2013 , 2835-2837 | | |
| 154 | Mouse Eerve Growth Factor 2013 , 2831-2833 | | |
| 153 | Rat Kallikrein 10, Salivary Gland Proteinase K 2013 , 2840-2841 | | |
| 152 | Mouse Proteinase F 2013 , 2833-2834 | | |
| 151 | Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 303, F1230-8 | 4.3 | 32 |
| 150 | Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. <i>Biological Chemistry</i> , 2010 , 391, 803-12 | 4.5 | 23 |

| | | | |
|-----|---|-----|----|
| 149 | Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. <i>Hypertension</i> , 2010 , 56, 260-7 | 8.5 | 60 |
| 148 | Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. <i>Biological Chemistry</i> , 2010 , 391, 345-55 | 4.5 | 74 |
| 147 | Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. <i>Biological Chemistry</i> , 2010 , 391, 411-23 | 4.5 | 48 |
| 146 | Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H1419-27 | 5.2 | 60 |
| 145 | Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H1048-54 | 5.2 | 35 |
| 144 | Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F1033-40 | 4.3 | 17 |
| 143 | Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. <i>BMC Cancer</i> , 2010 , 10, 245 | 4.8 | 26 |
| 142 | A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. <i>Experimental Cell Research</i> , 2010 , 316, 376-89 | 4.2 | 48 |
| 141 | Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. <i>Human Gene Therapy</i> , 2009 , 20, 147-58 | 4.8 | 38 |
| 140 | Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. <i>Journal of Biological Chemistry</i> , 2009 , 284, 35471-84 | 5.4 | 65 |
| 139 | Intermedin is a new angiogenic growth factor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H1040-7 | 5.2 | 44 |
| 138 | Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. <i>Laboratory Investigation</i> , 2008 , 88, 1157-66 | 5.9 | 49 |
| 137 | Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. <i>Life Sciences</i> , 2008 , 82, 156-65 | 6.8 | 36 |
| 136 | Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. <i>Human Gene Therapy</i> , 2008 , 19, 807-19 | 4.8 | 87 |
| 135 | Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. <i>Biological Chemistry</i> , 2008 , 389, 725-30 | 4.5 | 17 |
| 134 | Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. <i>Hypertension</i> , 2008 , 51, 1358-65 | 8.5 | 72 |
| 133 | Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. <i>Cardiovascular Research</i> , 2008 , 80, 354-64 | 9.9 | 44 |
| 132 | Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. <i>Toxicological Sciences</i> , 2008 , 102, 433-43 | 4.4 | 44 |

| | | | |
|-----|--|-----|----|
| 131 | Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. <i>Hypertension</i> , 2008 , 52, 715-20 | 8.5 | 48 |
| 130 | Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. <i>Journal of Cardiac Failure</i> , 2007 , 13, 588-96 | 3.3 | 22 |
| 129 | Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. <i>Cardiovascular Research</i> , 2007 , 73, 130-42 | 9.9 | 42 |
| 128 | Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5Smonophosphate-activated protein kinase signaling pathways. <i>Endocrinology</i> , 2007 , 148, 2016-26 | 4.8 | 45 |
| 127 | Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. <i>Hypertension</i> , 2007 , 49, 490-7 | 8.5 | 54 |
| 126 | Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. <i>Regulatory Peptides</i> , 2007 , 140, 12-20 | | 41 |
| 125 | Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. <i>Peptides</i> , 2007 , 28, 1383-9 | 3.8 | 35 |
| 124 | Upregulation of kallistatin expression in rheumatoid joints. <i>Journal of Rheumatology</i> , 2007 , 34, 2171-6 | 4.1 | 15 |
| 123 | Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 624-33 | 4.3 | 75 |
| 122 | Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. <i>Hypertension</i> , 2006 , 47, 752-61 | 8.5 | 82 |
| 121 | The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. <i>Biological Chemistry</i> , 2006 , 387, 665-75 | 4.5 | 51 |
| 120 | Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. <i>Human Gene Therapy</i> , 2006 , 17, 1201-13 | 4.8 | 65 |
| 119 | Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. <i>Human Gene Therapy</i> , 2006 , 17, 206-19 | 4.8 | 94 |
| 118 | Experimental therapy with tissue kallikrein against cerebral ischemia. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 1323-7 | 2.8 | 29 |
| 117 | Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. <i>Human Gene Therapy</i> , 2006 , 17, 545-55 | 4.8 | 48 |
| 116 | Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. <i>Life Sciences</i> , 2005 , 76, 2457-71 | 6.8 | 68 |
| 115 | Kallikrein-kinin in stroke, cardiovascular and renal disease. <i>Experimental Physiology</i> , 2005 , 90, 291-8 | 2.4 | 78 |
| 114 | Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1319-24 | | 78 |

| | | | |
|-----|---|------|-----|
| 113 | Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2005 , 289, F622-31 | 4.3 | 22 |
| 112 | Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. <i>Journal of Biological Chemistry</i> , 2005 , 280, 8022-30 | 5.4 | 98 |
| 111 | Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. <i>Diabetes</i> , 2005 , 54, 1573-80 | 0.9 | 59 |
| 110 | Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. <i>Hypertension</i> , 2004 , 43, 452-9 | 8.5 | 96 |
| 109 | Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. <i>Hypertension</i> , 2004 , 43, 109-16 | 8.5 | 112 |
| 108 | Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. <i>Kidney International</i> , 2004 , 66, 722-32 | 9.9 | 51 |
| 107 | Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. <i>Hypertension</i> , 2003 , 42, 1026-33 | 8.5 | 52 |
| 106 | Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 285, H1479-88 | 5.2 | 33 |
| 105 | Structural elements of kallistatin required for inhibition of angiogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2003 , 284, C1604-13 | 5.4 | 46 |
| 104 | Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. <i>Molecular and Cellular Biology</i> , 2003 , 23, 5726-37 | 4.8 | 220 |
| 103 | Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. <i>Journal of Biological Chemistry</i> , 2003 , 278, 219-25 | 5.4 | 57 |
| 102 | Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1279-85 | 9.4 | 85 |
| 101 | Association of the tissue kallikrein gene promoter with ESRD and hypertension. <i>Kidney International</i> , 2002 , 61, 1030-9 | 9.9 | 43 |
| 100 | Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. <i>Journal of Biological Chemistry</i> , 2002 , 277, 34708-16 | 5.4 | 52 |
| 99 | Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. <i>Circulation</i> , 2002 , 106, 993-9 | 16.7 | 67 |
| 98 | Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. <i>Hypertension</i> , 2002 , 40, 653-9 | 8.5 | 72 |
| 97 | Kallistatin is a new inhibitor of angiogenesis and tumor growth. <i>Blood</i> , 2002 , 100, 3245-52 | 2.2 | 145 |
| 96 | Adenovirus-mediated gene transfer for cardiovascular and renal diseases. <i>Methods in Enzymology</i> , 2002 , 346, 247-63 | 1.7 | 1 |

| | | | |
|----|---|------|-----|
| 95 | Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?. <i>Physiological Genomics</i> , 2001 , 7, 79-94 | 3.6 | 20 |
| 94 | Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. <i>Biological Chemistry</i> , 2001 , 382, 15-21 | 4.5 | 43 |
| 93 | Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. <i>Hypertension</i> , 2001 , 38, 136-41 | 8.5 | 67 |
| 92 | Identification of a major heparin-binding site in kallistatin. <i>Journal of Biological Chemistry</i> , 2001 , 276, 1276-84 | 5.4 | 43 |
| 91 | Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. <i>Circulation</i> , 2001 , 103, 125-32 | 16.7 | 167 |
| 90 | A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. <i>American Journal of Pathology</i> , 2001 , 159, 1797-805 | 5.8 | 52 |
| 89 | Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. <i>Peptides</i> , 2001 , 22, 1731-7 | 3.8 | 46 |
| 88 | Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 280, F964-71 | 4.3 | 50 |
| 87 | Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. <i>Kidney International</i> , 2000 , 58, 730-9 | 9.9 | 64 |
| 86 | Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse. <i>British Journal of Pharmacology</i> , 2000 , 130, 1076-82 | 8.6 | 11 |
| 85 | Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. <i>BBA - Proteins and Proteomics</i> , 2000 , 1479, 237-46 | | 28 |
| 84 | Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D. <i>The Protein Journal</i> , 2000 , 19, 411-8 | | 18 |
| 83 | Enhanced renal function in bradykinin B(2) receptor transgenic mice. <i>American Journal of Physiology - Renal Physiology</i> , 2000 , 278, F484-91 | 4.3 | 23 |
| 82 | Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. <i>Journal of Biological Chemistry</i> , 2000 , 275, 38457-66 | 5.4 | 35 |
| 81 | A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. <i>Journal of Biological Chemistry</i> , 2000 , 275, 40371-7 | 5.4 | 21 |
| 80 | Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. <i>FASEB Journal</i> , 2000 , 14, 1858-60 | 0.9 | 97 |
| 79 | Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. <i>Human Gene Therapy</i> , 2000 , 11, 1817-27 | 4.8 | 66 |
| 78 | Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. <i>Hypertension</i> , 2000 , 35, 25-31 | 8.5 | 104 |

| | | | |
|----|---|------|-----|
| 77 | Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. <i>Circulation Research</i> , 2000 , 86, 418-24 | 15.7 | 27 |
| 76 | Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 1459-66 | 9.4 | 24 |
| 75 | Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 2379-85 | 9.4 | 69 |
| 74 | Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. <i>Hypertension</i> , 2000 , 36, 995-1001 | 8.5 | 111 |
| 73 | Kallikrein-binding protein is induced by growth hormone in the dwarf rat. <i>FASEB Journal</i> , 1999 , 13, 1839-44 | 4.4 | 4 |
| 72 | Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 276, F476-84 | 4.3 | 17 |
| 71 | Specificity of human tissue kallikrein towards substrates containing Phe ² Phe pair of amino acids. <i>Biochemical Journal</i> , 1999 , 339, 473-479 | 3.8 | 21 |
| 70 | Localization and expression of tissue kallikrein and kallistatin in human blood vessels. <i>Journal of Histochemistry and Cytochemistry</i> , 1999 , 47, 221-8 | 3.4 | 66 |
| 69 | Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. <i>Hypertension</i> , 1999 , 34, 164-70 | 8.5 | 47 |
| 68 | Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. <i>Hypertension</i> , 1999 , 33, 219-24 | 8.5 | 39 |
| 67 | Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. <i>Immunopharmacology</i> , 1999 , 44, 137-43 | | 16 |
| 66 | Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. <i>Immunopharmacology</i> , 1999 , 44, 57-65 | | 33 |
| 65 | The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. <i>British Journal of Pharmacology</i> , 1999 , 126, 1769-76 | 8.6 | 31 |
| 64 | Gene therapy for hypertension: a review of potential targets. <i>BioDrugs</i> , 1999 , 11, 43-53 | 7.9 | 4 |
| 63 | Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. <i>Clinical and Experimental Hypertension</i> , 1999 , 21, 1145-60 | 2.2 | 16 |
| 62 | Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. <i>Stroke</i> , 1999 , 30, 1925-31; discussion 1931-2 | 6.7 | 34 |
| 61 | Molecular cloning and expression of rat bradykinin B1 receptor. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998 , 1442, 177-85 | | 49 |
| 60 | Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. <i>Kidney International</i> , 1998 , 54, 1250-60 | 9.9 | 44 |

| | | | |
|----|--|-----|-----|
| 59 | Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. <i>Kidney International</i> , 1998 , 53, 1305-13 | 9.9 | 38 |
| 58 | Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 244, 449-54 | 3.4 | 16 |
| 57 | Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. <i>Human Gene Therapy</i> , 1998 , 9, 21-31 | 4.8 | 92 |
| 56 | Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. <i>Human Gene Therapy</i> , 1998 , 9, 1429-38 | 4.8 | 55 |
| 55 | Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. <i>Hypertension</i> , 1998 , 31, 1104-10 | 8.5 | 84 |
| 54 | Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. <i>Journal of Biological Chemistry</i> , 1998 , 273, 2784-91 | 5.4 | 111 |
| 53 | Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. <i>Human Gene Therapy</i> , 1997 , 8, 1753-61 | 4.8 | 38 |
| 52 | Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. <i>Hypertension</i> , 1997 , 29, 488-93 | 8.5 | 71 |
| 51 | Kallikrein-kinin system and blood pressure sensitivity to salt. <i>Hypertension</i> , 1997 , 29, 471-7 | 8.5 | 32 |
| 50 | Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. <i>Human Gene Therapy</i> , 1997 , 8, 341-7 | 4.8 | 45 |
| 49 | Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. <i>Life Sciences</i> , 1997 , 60, 1431-5 | 6.8 | 33 |
| 48 | Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. <i>American Journal of Physiology - Renal Physiology</i> , 1997 , 273, F783-9 | 4.3 | 2 |
| 47 | Regulation of bradykinin B2-receptor expression by oestrogen. <i>British Journal of Pharmacology</i> , 1997 , 121, 1763-9 | 8.6 | 55 |
| 46 | Kallistatin in blood pressure regulation transgenic and somatic gene delivery studies. <i>Trends in Cardiovascular Medicine</i> , 1997 , 7, 307-11 | 6.9 | 8 |
| 45 | DNA polymorphisms in the 5Sflanking region of the human tissue kallikrein gene. <i>Human Genetics</i> , 1997 , 99, 727-34 | 6.3 | 26 |
| 44 | Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. <i>Immunopharmacology</i> , 1997 , 36, 221-7 | | 15 |
| 43 | Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. <i>Hypertension</i> , 1997 , 30, 307-13 | 8.5 | 73 |
| 42 | Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. <i>Hypertension Research</i> , 1997 , 20, 269-77 | 4.7 | 45 |

| | | | |
|----|---|-----|----|
| 41 | DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. <i>Human Genetics</i> , 1997 , 99, 727 | 6.3 | 22 |
| 40 | Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. <i>Genomics</i> , 1996 , 31, 51-7 | 4.3 | 95 |
| 39 | High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. <i>Clinical and Experimental Hypertension</i> , 1996 , 18, 975-93 | 2.2 | 24 |
| 38 | Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. <i>Translational Research</i> , 1996 , 127, 612-20 | | 96 |
| 37 | The purification of human urinary kallikrein with ion-exchange radial flow membrane chromatography. <i>Biomedical Chromatography</i> , 1996 , 10, 139-43 | 1.7 | 8 |
| 36 | Tissue kallikreins in evolutionarily diverse vertebrates. <i>Immunopharmacology</i> , 1996 , 32, 94-5 | | 2 |
| 35 | High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. <i>Immunopharmacology</i> , 1996 , 32, 105-7 | | 12 |
| 34 | Tissue kallikrein inhibitors in mammals. <i>Immunopharmacology</i> , 1996 , 32, 67-72 | | 11 |
| 33 | Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. <i>Journal of Biological Chemistry</i> , 1996 , 271, 27590-4 | 5.4 | 26 |
| 32 | Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. <i>Human Gene Therapy</i> , 1996 , 7, 901-11 | 4.8 | 40 |
| 31 | Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. <i>Current Eye Research</i> , 1996 , 15, 1117-23 | 2.9 | 38 |
| 30 | Functional analysis of human tissue kallikrein in transgenic mouse models. <i>Hypertension</i> , 1996 , 27, 491-48.5 | | 21 |
| 29 | Antisense inhibition of the brain kallikrein-kinin system. <i>Hypertension</i> , 1996 , 28, 980-7 | 8.5 | 14 |
| 28 | Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. <i>Kidney International</i> , 1995 , 48, 690-7 | 9.9 | 44 |
| 27 | Urinary Levels of Kallikrein and Kallistatin in Pregnancy-Induced Hypertension. <i>Hypertension in Pregnancy</i> , 1995 , 14, 201-212 | 2 | 2 |
| 26 | Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. <i>Journal of Biological Chemistry</i> , 1995 , 270, 451-5 | 5.4 | 40 |
| 25 | Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. <i>Hypertension</i> , 1995 , 25, 715-9 | 8.5 | 54 |
| 24 | Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. <i>Hypertension</i> , 1995 , 26, 847-53 | 8.5 | 53 |

| | | | |
|----|---|-----|-----|
| 23 | Activation of serpins and their cognate proteases in muscle after crush injury. <i>Journal of Cellular Physiology</i> , 1994 , 159, 11-8 | 7 | 32 |
| 22 | Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. <i>Genomics</i> , 1994 , 23, 362-9 | 4.3 | 136 |
| 21 | Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). <i>Genomics</i> , 1994 , 23, 370-8 | 4.3 | 27 |
| 20 | Differential developmental expression of the rat kininogen genes. <i>Pediatric Research</i> , 1992 , 32, 649-53 | 3.2 | 7 |
| 19 | Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. <i>Biochemistry</i> , 1992 , 31, 10922-8 | 3.2 | 14 |
| 18 | Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing. <i>Biochemistry</i> , 1992 , 31, 4969-74 | 3.2 | 47 |
| 17 | Glandular kallikrein gene expression is selectively down-regulated by glucocorticoids in pancreatic AR42J cells. <i>Endocrinology</i> , 1991 , 128, 2216-22 | 4.8 | 18 |
| 16 | Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1991 , 1129, 127-30 | | 14 |
| 15 | Kallikrein Multigene Families and the Regulation of Their Expression. <i>Journal of Cardiovascular Pharmacology</i> , 1990 , 15, S7-S16 | 3.1 | 64 |
| 14 | Human urinary kallikrein. Complete amino acid sequence and sites of glycosylation. <i>International Journal of Peptide and Protein Research</i> , 1989 , 33, 237-49 | | 24 |
| 13 | Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. <i>Journal of Hypertension</i> , 1989 , 7, 865-71 | 1.9 | 49 |
| 12 | Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization. <i>Advances in Experimental Medicine and Biology</i> , 1989 , 247B, 1-8 | 3.6 | 5 |
| 11 | Circulating autoantibodies to mammalian tissue kallikreins. <i>Experimental Biology and Medicine</i> , 1988 , 187, 320-6 | 3.7 | 4 |
| 10 | A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. <i>Journal of Hypertension</i> , 1988 , 6, 551-7 | 1.9 | 38 |
| 9 | Tissue kallikrein in rat brain and pituitary: regional distribution and estrogen induction in the anterior pituitary. <i>Endocrinology</i> , 1987 , 120, 475-82 | 4.8 | 106 |
| 8 | Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1987 , 910, 233-9 | | 22 |
| 7 | Sex dimorphism and hormonal regulation of rat tissue kallikrein mRNA. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1986 , 867, 16-23 | | 27 |
| 6 | Kallikrein activation of a high molecular weight atrial peptide. <i>Biochemical and Biophysical Research Communications</i> , 1984 , 120, 461-6 | 3.4 | 56 |

| | | | |
|---|---|-----|-----|
| 5 | Differential effects of testosterone, thyroxine, and cortisol on rat submandibular gland versus renal kallikrein. <i>Endocrinology</i> , 1983 , 113, 2221-5 | 4.8 | 46 |
| 4 | A method for determination of human urinary inactive kallikrein (prekallikrein). <i>Tohoku Journal of Experimental Medicine</i> , 1982 , 137, 269-74 | 2.4 | 13 |
| 3 | A simple procedure for high efficiency counting of labeled protein bands in polyacrylamide slab gels. <i>Electrophoresis</i> , 1981 , 2, 60-63 | 3.6 | 6 |
| 2 | The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980 , 51, 840-8 | 5.6 | 114 |
| 1 | Isozymes of rat urinary kallikrein. <i>Biochemical Pharmacology</i> , 1979 , 28, 2071-9 | 6 | 69 |